Gene delivery technologies company VectorBuilder has opened a new office in Edinburgh, hoping to bolster its presence in the United Kingdom.
The new location is part of Edinburgh Technopole, a Pioneer Group in Midlothian Science Zone.
“When it comes to published scientific research, the UK is ranked third in the world with nearly 200,000 citable publications in 2020. With VectorBuilder’s UK team rapidly growing and an organisational commitment to scientific research, it made sense for VectorBuilder to open an office in the country,” said Christina McClure, Associate Sales Director of Europe, UK, and Scandinavia of VectorBuilder.
The company previously participated in the first human trial of a gene therapy drug candidate for Menkes disease, and recently partnered with Stand Up Therapeutics to produce and supply gene therapy products for the treatment of paralysis.
“As a provider of AAV viral vectors, VectorBuilder has played a crucial role in freeing up our time to focus more on research by providing large quantities of high-quality viral vector for in vivo applications,” said Martin Madill, Senior Scientist at Purespring Therapeutics.
